Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £2.15m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Options Award

23 Dec 2025 07:00

RNS Number : 5646M
Physiomics PLC
23 December 2025
 

23 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):

1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.

2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025. One third of these Options vest on each anniversary of Mr Thissen's employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1 July 2028)

3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to the closing mid-market price per Ordinary Share on 22 December 2025. These Options vest over the same time periods as described under (2) above.

All Options can be exercised within 10 years of the date of grant.

The total number of options issued to date under the Scheme is 4,548,132.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"As the Company pursues growth and a transition to cash generation, the establishment of a scalable second service line represents a significant milestone in this strategy. We are pleased to announce that following Jesse's appointment in July 2025, he has played an integral role in launching our new Biometrics service line. Within the first six months, he has secured and commenced delivery on three contracts supporting new therapies for infectious and immunological diseases. Jesse has demonstrated strong leadership in advancing the Biometrics service line and continues to contribute effectively across the broader organisation."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZMZZZZKGKZZ
Date   Source Headline
15th May 20201:00 pmRNSHolding(s) in Company
28th Apr 20202:50 pmRNSConference attendance and presentation
16th Apr 20207:00 amRNSConfirmation of Twitter account
9th Apr 202012:28 pmRNSHolding(s) in Company
6th Apr 20207:00 amRNSAwarded further Bicycle Therapeutics contract
19th Mar 20207:00 amRNSCOVID-19 update
10th Mar 20207:00 amRNSNIHR i4i award
5th Mar 20207:00 amRNSPhysiomics awarded further contract by Merck
3rd Mar 20207:00 amRNSAwarded two further contracts by Bicycle
27th Dec 20193:45 pmRNSHolding(s) in Company
23rd Dec 20197:00 amRNSContract award
20th Dec 201910:30 amRNSMerck Contracts
19th Nov 201912:52 pmRNSResult of AGM
21st Oct 20197:00 amRNSDispatch of Annual Report and Notice of AGM
30th Sep 20197:00 amRNSFinal Results for the Year Ended 30 June 2019
5th Aug 20197:00 amRNSDirector Dealing
30th Jul 20197:00 amRNSTrading Update
22nd Jul 20199:03 amRNSHolding(s) in Company
8th Jul 20197:00 amRNSAgreement with Bicycle and Cancer Research UK
2nd Jul 20191:30 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSContract Award
31st May 20197:00 amRNSChange of Adviser
14th May 20197:00 amRNSInnovate UK Award Project
3rd May 201912:00 pmRNSPhysiomics participates at NIHR event
30th Apr 20192:00 pmRNSConference attendance and presentation
27th Mar 20191:00 pmRNSIssue of Options
26th Mar 20191:00 pmRNSAIM Rule 26 Website Change
20th Mar 20197:00 amRNSConference Attendance and Presentation
21st Feb 20197:00 amRNSInterim Results
7th Jan 20197:00 amRNSConference Attendance
3rd Jan 20197:00 amRNSStrategic Collaboration
17th Dec 20187:00 amRNSRenewal of Agreement with Merck
20th Nov 201812:56 pmRNSResult of AGM
15th Oct 20181:00 pmRNSDispatch of Annual Report and Shareholder Circular
8th Oct 20187:00 amRNSFinal Results for the Year Ended 30 June 2018
9th Aug 20187:00 amRNSContract award
2nd Jul 20181:57 pmRNSPhysiomics Expands Technical Team
21st Jun 20187:00 amRNSTrading Update
11th Jun 20184:05 pmRNSUpdated Website
23rd May 20187:00 amRNSPlacing
26th Apr 201811:06 amRNSContract Award
6th Apr 20182:40 pmRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSPhysiomics to Present at AACR Annual Meeting
27th Mar 20185:23 pmRNSIssue of Options
14th Mar 20187:00 amRNSAward of New Innovate UK Grant
12th Mar 20187:00 amRNSCompletion of Innovate UK Grant Project
19th Feb 20187:00 amRNSInterim Results Statement
9th Feb 20187:00 amRNSContract Award
26th Jan 20187:00 amRNSNew Major Pharmaceutical Client
25th Jan 20181:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.